Approval · Notice of Compliance 35142 · 2025
DULOXETINE: Notice of Compliance 35142
Issued April 8, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35142
- Date
- April 8, 2025
- Company
- Laboratoire Riva Inc.Blainville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Update to labelling (to match Licensor)
- Canadian reference product
- CYMBALTA (Eli Lilly Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DULOXETINE | Not yet assigned | — |
Medicinal ingredients
- DULOXETINE HYDROCHLORIDE 30 MG per CAP
- DULOXETINE HYDROCHLORIDE 60 MG per CAP